Hoffmann-La_Roche%D9%87%D9%88%D9%81%D9%85%D8%A7%D9%86-%D9%84%D8%A7_%D8%B1%D9%88%D8%B4%D9%87%D9%88%D9%81%D9%85%D8%A7%D9%86-%D9%84%D8%A7_%D8%B1%D9%88%D8%B4Hoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann%E2%80%93La_Roche%D9%87%D9%88%D9%81%D9%85%D8%A7%D9%86-%D9%84%D8%A7_%D8%B1%D9%88%D8%B4Hoffmann-La_RocheRoche_(entreprise)%D7%94%D7%95%D7%A4%D7%9E%D7%9F_%D7%9C%D7%94_%D7%A8%D7%95%D7%A9Hoffmann-La_RocheHoffmann-La_Roche%E3%82%A8%E3%83%95%E3%83%BB%E3%83%9B%E3%83%95%E3%83%9E%E3%83%B3%E3%83%BB%E3%83%A9%E3%83%BB%E3%83%AD%E3%82%B7%E3%83%A5%ED%98%B8%ED%94%84%EB%A7%8C_%EB%9D%BC_%EB%A1%9C%EC%8A%88Hoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann-La_RocheHoffmann%E2%80%93La_RocheHoffmann%E2%80%93La_RocheRoche_HoldingHoffmann-La_RocheHoffmann-La_RocheHofman_la_Ro%C5%A1Hoffmann-La_Roche%E0%B8%AE%E0%B8%AD%E0%B8%9F%E0%B8%9F%E0%B9%8C%E0%B9%81%E0%B8%A1%E0%B8%99-%E0%B8%A5%E0%B8%B2_%E0%B9%82%E0%B8%A3%E0%B8%8ARoche_(firma)Hoffmann-La_RocheQ212646%E7%BD%97%E6%B0%8F
about
Theodor SprollWilliam M. BurnsValentine RugwabizaStefan AignerJoao C GuimaraesMarkus BritschgiUlrich BrinkmannBaran KoçTjaart De BeerTony ChristopeitRené PetersJürg Oliver StraubXavier LucasJan TschicholdMarkus von KienlinKarsten MaederRoberto VillaseñorMarianne ManchesterTobias SchmidtPlacidus PlattnerPeter WestenskowTimothy K CraigJana ZielinskiMartin FitznerSimon HauriSofía ArriaránSebastian FuchsJohan PradeillesOtto FajardoBenjamin J StentonDaniel S ChenFrancois MercierBikramjit ChopraFabio SambataroMichael A MaurerPascal F TripetJoachim LoupJonathan P. MochelJesse AldersonAlexandra Reichenbach
P108
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC PatientsSAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerComparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After ProstatectomyPreemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage ADescriptive Observational Study ALK-2016-CPHGAPI-CAT STUDY for APIxaban Cancer Associated ThrombosisStudy of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HLPhase 2 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney InjuryAssessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology
P6153
description
Läkemedelsföretag
@sv
Schweizer Pharmakonzern
@de
Swiss healthcare company
@en
bedrijf in Zwitserland
@nl
entreprise pharmaceutique suisse
@fr
multinazionale farmaceutica
@it
İsviçre kökenli çokuluslu ilaç firması
@tr
חברה
@he
スイスの製薬会社
@ja
name
Hoffmann-La Roche
@bg
Hoffmann-La Roche
@ca
Hoffmann-La Roche
@cs
Hoffmann-La Roche
@da
Hoffmann-La Roche
@de
Hoffmann-La Roche
@en
Hoffmann-La Roche
@eo
Hoffmann-La Roche
@es
Hoffmann-La Roche
@fi
Hoffmann-La Roche
@fr
type
label
Hoffmann-La Roche
@bg
Hoffmann-La Roche
@ca
Hoffmann-La Roche
@cs
Hoffmann-La Roche
@da
Hoffmann-La Roche
@de
Hoffmann-La Roche
@en
Hoffmann-La Roche
@eo
Hoffmann-La Roche
@es
Hoffmann-La Roche
@fi
Hoffmann-La Roche
@fr
altLabel
F. Hoffmann-La Roche AG
@de
F. Hoffmann-La Roche AG
@en
Hoffmann-la roche
@fr
Roche
@en
ロシュ
@ja
ロシュ・ホールディング
@ja
prefLabel
Hoffmann-La Roche
@bg
Hoffmann-La Roche
@ca
Hoffmann-La Roche
@cs
Hoffmann-La Roche
@da
Hoffmann-La Roche
@de
Hoffmann-La Roche
@en
Hoffmann-La Roche
@eo
Hoffmann-La Roche
@es
Hoffmann-La Roche
@fi
Hoffmann-La Roche
@fr